Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. ACN
3. NVDA
4. MU
5. GOOGL
6. APGE
7. DFTX
8. LCO
9. KR
10. MSTR

Go back to Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer
(NASDAQ: CADL) Delayed: 8.94 +0.63 (7.58%)
Previous Close $8.31    52 Week High $ 
Open $8.41    52 Week Low $ 
Day High $8.99    P/E N/A 
Day Low $8.39    EPS $ 
Volume 726,225